Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.05 and traded as high as $0.08. Mateon Therapeutics shares last traded at $0.07, with a volume of 173,091 shares traded.
Mateon Therapeutics Price Performance
The business’s 50-day simple moving average is $0.05 and its two-hundred day simple moving average is $0.05.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Airline Stocks – Top Airline Stocks to Buy Now
- Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
- 3 Small Caps With Big Return Potential
- Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
- Are Penny Stocks a Good Fit for Your Portfolio?
- This ETF Weeds Out Small-Cap Underperformers
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
